Comparative Pharmacology
Head-to-head clinical analysis: BYVALSON versus EDARBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYVALSON versus EDARBI.
BYVALSON vs EDARBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.
Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
160 mg orally once daily.
EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.
None Documented
None Documented
Terminal half-life 10-12 hours; allows once-daily dosing; extended in severe renal impairment (up to 20 hours)
Approximately 20-22 hours in normal subjects; allows once-daily dosing. Half-life increases in moderate to severe hepatic impairment.
Renal: 60% unchanged; Biliary/Fecal: 40% as metabolites; total clearance ~30 L/h
Approximately 60% of dose is excreted in feces (primarily as unchanged drug) and 33% in urine (as metabolites, predominantly glucuronide conjugates).
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker